ABBV vs BLK: Which Is the Better Buy?
Side-by-side comparison of AbbVie Inc. and BlackRock, Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-22.
AbbVie Inc. · Healthcare
$208.05
+4.5% upside to fair value
Grade C
High Quality
VS
BlackRock, Inc. · Financial Services
$1,042.85
+125.5% upside to fair value
Grade A
High Quality
QuantHub Verdict
BLK has more upside to fair value
(+125.5%).
ABBV trades at a lower forward P/E
(14.9x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
ABBV |
BLK |
| Current Price |
$208.05 |
$1,042.85 |
| Fair Value Estimate |
$217.50 |
$2,351.12 |
| Upside to Fair Value |
+4.5%
|
+125.5%
|
| Market Cap |
$367.9B |
$162.2B |
| Forward P/E |
14.9x
|
25.9x
|
| EV / EBITDA |
16.7x
|
16.9x
|
| Price / Sales |
6.1x
|
6.3x
|
| Price / FCF |
20.9x
|
45.2x
|
| Revenue Growth YoY |
+8.6%
|
+28.3%
|
| Gross Margin |
83.7%
|
59.1%
|
| Operating Margin |
34.7%
|
29.9%
|
| Return on Equity |
-129.24%
|
12.0%
|
| Dividend Yield |
3.2% |
0% |
| FCF Yield |
4.78%
|
2.21%
|
| Analyst Consensus |
Buy
|
Strong Buy
|
Investment Thesis
AbbVie is a leading diversified biopharmaceutical company navigating the post-Humira transition with strong momentum from Skyrizi and Rinvoq in immunology and continued growth in neuroscience. Full-year 2025 revenue reached $61.2 billion with a gross margin of 83.7% and operating margin of 34.7%, demonstrating operational strength despite the ongoing Humira erosion. Management guides to $67 billi…
BlackRock, Inc. is the world's largest asset manager with over $14 trillion in assets under management, operating primarily in financial services and asset management. The company benefits from a durable competitive moat driven by its scale, technology platform Aladdin, and founder-led management with CEO Laurence D. Fink at the helm since inception. BlackRock exhibits strong fundamentals includi…
Accumulation Zones
| Metric |
ABBV |
BLK |
| Zone Low |
$163.13 |
$1,763.34 |
| Zone High |
$184.88 |
$1,998.45 |
| In Buy Zone? |
No
|
Yes
|